SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).

Employees

Sector

Biotechnology & Medical Research

Calendar

03-22 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
23/01/26	1,984.00 ¥	+4.97%	1,295,200
22/01/26	1,890.00 ¥	-0.47%	648,700
21/01/26	1,899.00 ¥	-0.89%	854,700
20/01/26	1,916.00 ¥	-5.20%	1,666,300
19/01/26	2,021.00 ¥	+3.69%	1,630,400

Delayed Quote Japan Exchange, January 23, 2026 at 06:30 am

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1,984.00JPY

Average target price

2,050.00JPY

Spread / Average Target

+3.33%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 06:30:00 23/01/2026 GMT			5-day change	1st Jan Change
1,984.00 ^JPY	+4.97%		+1.80%	+17.40%

12-15	SanBio Widens Nine-Month Loss	MT
12-09	SanBio's Brain Therapy AKUUGO Clears Key Regulatory Hurdle in Japan	MT

Capitalization	155B 981M 834M 773M 723M 1.35B 90.14B 1.43B 8.84B 3.51B 42.56B 3.68B 3.6B	P/E ratio 2026 *	-36.5x	P/E ratio 2027 *	-90.4x
Enterprise value	156B 988M 841M 779M 728M 1.36B 90.8B 1.44B 8.9B 3.53B 42.87B 3.71B 3.63B	EV / Sales 2026 *	5,316x	EV / Sales 2027 *	45.6x
Free-Float	69.66%	Yield 2026 *	-	Yield 2027 *	-

12-15	SanBio Widens Nine-Month Loss	MT
12-09	SanBio's Brain Therapy AKUUGO Clears Key Regulatory Hurdle in Japan	MT
12-09	Sanbio Obtains Partial Change Approval For?Akuugo(R) Suspension for Intracranial Implantation	CI
11-06	SanBio Seeks 14.5 Billion Yen via International Offering	MT
17/10/25	Jefferies Adjusts SanBio's Price Target to 1,250 Yen From 1,010 Yen, Keeps at Underperform	MT
16/10/25	SanBio Co., Ltd. Announces Partial Change Approval for AKUUGO Suspension for Intracranial Implantation	CI
02/10/25	SanBio Co., Ltd. Announces Inclusion of AKUUGO Suspension for Intracranial Implantation on the Committee Agenda	CI
25/09/25	Jefferies Adjusts SanBio's Price Target to 1,010 Yen From 840 Yen, Keeps at Underperform	MT
18/09/25	SanBio Company Limited, Q2 2026 Earnings Call, Sep 18, 2025
12/09/25	SanBio's Loss Widens in Fiscal H1	MT
12/09/25	SanBio Company Limited Revises Consolidated Earnings Guidance for the Full Fiscal Year Ending January 31, 2026	CI
18/07/25	Sanbio Company Limited Announces New Credit Line Agreement Supports Akuugo Commercialization Efforts	CI
26/06/25	Nomura Downgrades SanBio Company to Neutral from Buy; Price Target is 2,900 Yen	MT

17/10/25	Jefferies Adjusts SanBio's Price Target to 1,250 Yen From 1,010 Yen, Keeps at Underperform	MT
02/10/25	SanBio Co., Ltd. Announces Inclusion of AKUUGO Suspension for Intracranial Implantation on the Committee Agenda	CI
25/09/25	Jefferies Adjusts SanBio's Price Target to 1,010 Yen From 840 Yen, Keeps at Underperform	MT
26/06/25	Nomura Downgrades SanBio Company to Neutral from Buy; Price Target is 2,900 Yen	MT
16/06/25	Jefferies Adjusts SanBio's Price Target to 840 Yen From 280 Yen, Keeps at Underperform	MT

SanBio Company Limited Share Price

Equities

4592

JP3336750009

Biotechnology & Medical Research

Valuation: SanBio Company Limited

Chart: SanBio Company Limited

Latest news: SanBio Company Limited

Last Transcript: SanBio Company Limited

Analysts' recommendations: SanBio Company Limited

Press Releases: SanBio Company Limited

News in other languages: SanBio Company Limited

Quotes and Performance

Course Extremes

Managers and Directors: SanBio Company Limited

ETFs: SanBio Company Limited

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

01/08/24	SanBio Obtains Marketing Approval for AKUUGO Suspension for Intracranial Implantation as a Therapeutic Agent for Improving Chronic Motor Paralysis from Traumatic Brain Injury	AQ
31/07/24	SanBio Obtains Marketing Approval for “AKUUGO® Suspension for Intracranial Implantation” (INN: Vandefitemcel) as a Therapeutic Agent for Improving Chronic Motor Paralysis From Traumatic Brain Injury (TBI)	BU
16/08/22	SanBio : Announcement on Granting Stock Options (Share Acquisition Rights)	PU
01/08/22	SanBio : Notice regarding appointment of new corporate officers	PU
22/07/22	SanBio : Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan	PU

21/10/22	Tokyo finit la semaine en baisse, les taux américains inquiètent
18/12/19	L'hypothèse d'un Brexit dur rend moroses les Bourses asiatiques
18/12/19	Tokyo chute malgré les records de Wall Street
18/12/19	Tokyo en repli à l'ouverture
16/12/19	Les Bourses d'Asie en ordre dispersé après l'accord sino-américain

1 day	+4.97%
1 week	+1.80%
Current month	+17.40%
1 month	+22.54%
3 months	-28.01%
6 months	-8.32%
Current year	+17.40%

1 week	1,850	2,031
1 month	1,575	2,031
Current year	1,625	2,031
1 year	707	3,990
3 years	380	3,990
5 years	380	3,990
10 years	380	12,730

Manager	Title	Age	Since
Keita Mori CEO	Chief Executive Officer	58	26/02/2013
Shinya Hirata CTO	Chief Tech/Sci/R&D Officer	-	-
Chris sanbio Horan CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Toru Kawanishi CHM	Chairman	58	26/02/2013
Keita Mori BRD	Director/Board Member	58	26/02/2013
Noboru Kotani BRD	Director/Board Member	69	28/02/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SANBIO COMPANY LIMITED	+4.97%	+1.80%	+185.06%	+169.93%	981M
ARGENX SE	+0.29%	+1.07%	+13.32%	+93.11%	50.44B
WUXI APPTEC CO., LTD.	0.00%	-6.42%	+79.48%	+0.10%	41.86B
INSMED INCORPORATED	-2.61%	-3.23%	+100.68%	+633.04%	33.32B
BIONTECH SE	-2.10%	+6.40%	-5.03%	-19.31%	29.1B
WUXI BIOLOGICS (CAYMAN) INC.	+0.92%	-1.16%	+123.92%	-44.89%	20.84B
GENMAB A/S	+0.57%	-2.52%	+40.87%	-21.72%	20.67B
SUMMIT THERAPEUTICS INC.	-5.07%	-3.23%	-33.10%	+269.73%	12.72B
AKESO, INC.	+3.65%	-3.72%	+91.30%	+143.72%	13.76B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.07%	-9.33%	+163.56%	-	12.85B
Average	+0.37%	-1.33%	+76.01%	+135.97%	23.65B
Weighted average by Cap.	-0.31%	-0.83%	+58.14%	+131.52%

	2026 *	2027 *
Net sales	29.33M 186K 158K 147K 137K 255K 17.08M 271K 1.67M 665K 8.06M 697K 683K	3.42B 21.66M 18.42M 17.07M 15.96M 29.75M 1.99B 31.53M 195M 77.47M 940M 81.22M 79.56M
Net income	-3.98B -25.21M -21.44M -19.87M -18.57M -34.62M -2.32B -36.69M -227M -90.16M -1.09B -94.52M -92.58M	-1.62B -10.25M -8.72M -8.08M -7.55M -14.08M -942M -14.93M -92.38M -36.68M -445M -38.45M -37.66M
Net Debt	1.13B 7.14M 6.07M 5.63M 5.26M 9.8M 656M 10.39M 64.3M 25.53M 310M 26.76M 26.21M	1.01B 6.43M 5.47M 5.07M 4.74M 8.83M 591M 9.36M 57.91M 22.99M 279M 24.1M 23.61M